Silco Pharmaceuticals Limited

DSE:SILCOPHL Stock Report

Market Cap: ৳1.7b

Silco Pharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Md. Haque Rukan

Chief executive officer

৳540.0k

Total compensation

CEO salary percentage100.0%
CEO tenureno data
CEO ownershipn/a
Management average tenureno data
Board average tenureno data

Recent management updates

Recent updates

CEO Compensation Analysis

How has Md. Haque Rukan's remuneration changed compared to Silco Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2024n/an/a

৳43m

Dec 31 2023n/an/a

৳48m

Sep 30 2023n/an/a

৳50m

Jun 30 2023৳540k৳540k

৳69m

Mar 31 2023n/an/a

৳68m

Dec 31 2022n/an/a

৳82m

Sep 30 2022n/an/a

৳79m

Jun 30 2022৳540k৳540k

৳84m

Mar 31 2022n/an/a

৳88m

Dec 31 2021n/an/a

৳87m

Sep 30 2021n/an/a

৳86m

Jun 30 2021৳540k৳540k

৳85m

Mar 31 2021n/an/a

৳84m

Dec 31 2020n/an/a

৳76m

Sep 30 2020n/an/a

৳88m

Jun 30 2020৳540k৳540k

৳83m

Mar 31 2020n/an/a

৳163m

Dec 31 2019n/an/a

৳167m

Sep 30 2019n/an/a

৳168m

Jun 30 2019৳540k৳540k

৳162m

Mar 31 2019n/an/a

৳106m

Dec 31 2018n/an/a

৳105m

Sep 30 2018n/an/a

৳104m

Jun 30 2018৳540kn/a

৳105m

Compensation vs Market: Md.'s total compensation ($USD4.50K) is below average for companies of similar size in the BD market ($USD21.97K).

Compensation vs Earnings: Md.'s compensation has been consistent with company performance over the past year.

CEO

Md. Haque Rukan (71 yo)

no data

Tenure

৳540,000

Compensation

Dr. Md. Badrul Haque Rukan serves as the Managing Director and Director of Silco Pharmaceuticals Ltd. Dr. Rukan is a prominent Child Specialist is Sylhet city completed his MBBS, DCH from DUB, also achieve...

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 04:15
End of Day Share Price 2024/12/24 00:00
Earnings2024/03/31
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Silco Pharmaceuticals Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution